|
14.01.2016 14:50:31
|
DGAP-News: Formycon AG
DGAP-News: Formycon AG: Formycon files multiple patent applications for the pharmaceutical formulation and delivery of intraocular VEGF antagonists
Munich - Formycon AG, the biosimilars company, today announced that it has filed already three patent applications relating to the formulation and intraocular delivery of VEGF antagonists. The first international patent application related to a silicone-free pre-filled plastic syringe has been recently published (International Publication Number WO 2015/173260 Al).
VEGF antagonists ranibizumab and aflibercept are commonly used to treat age dependent eye diseases such as wet macular degeneration. The market size for intraocular anti-VEGF therapy is rapidly increasing with a current volume of about USD 6.9 billion.
Pre-filled syringes have many benefits compared to a vial and a separately provided syringe, such as improved convenience, safety, accuracy, sterility, and affordability. The use of pre-filled syringes results in greater dose precision, in a reduction of the potential for needle stick injuries that can occur while drawing medication from vials, in pre-measured dosage reducing dosing errors and sterility problems due to the need to reconstitute medication or draw it into a syringe, and in less overfilling of the syringe helping to reduce costs by minimising drug waste.
Silicone-free prefilled plastic syringes containing a VEGF antagonist will present an innovative way of drug administration for intraocular injection. Compared to glass syringes this new injection technology offers the potential for improved safety and convenience for patients and healthcare professionals as they are resistant to breakage and have a lower weight. Furthermore, it has been shown that silicone oil from standard glass or plastic syringes might migrate into the drug solution, cause drug inactivation, and accumulates in the vitreous cavity after intravitreal administration of VEGF antagonists.
Dr. Carsten Brockmeyer, CEO of Formycon AG, said "We are pleased to provide a potential improved way to accurately and safely administer VEGF antagonist in the eye. Our patent applications cover a broad range of VEGF antagonist formulations and injection devices. This underlines our mission to develop high quality biosimilars to treat eye diseases, one of the most rapidly growing therapeutic areas."
Formycon and its license partner bioeq GmbH, Holzkirchen, Germany, recently announced the initiation of a pivotal Phase III clinical trial with FYB201, an investigational biosimilar ranibizumab (Lucentis(R)*).
* Lucentis is a registered trademark of Genentech Inc.
About Formycon: Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon's specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.
Contact: Thorsten Schüller Corporate Communications and Investor Relations Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg/Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 Thorsten.schueller@formycon.com // www.formycon.com
Disclaimer: This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. With respect to pipeline products there can be no guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended.
This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.
---------------------------------------------------------------------------
14.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English Company: Formycon AG Fraunhoferstraße 15 82152 Planegg-Martinsried Germany Phone: 089 864667 100 Fax: 089 864667 110 Internet: www.formycon.com ISIN: DE000A1EWVY8 WKN: A1EWVY Listed: Regulated Unofficial Market in Berlin; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------
429447 14.01.2016
DGAP-News: Formycon AG / Key word(s): Patent
Formycon AG: Formycon files multiple patent applications for the
pharmaceutical formulation and delivery of intraocular VEGF antagonists
14.01.2016 / 14:50
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // January 14, 2016
Formycon files multiple patent applications for the pharmaceutical
formulation and delivery of intraocular VEGF antagonists
Munich - Formycon AG, the biosimilars company, today announced that it has filed already three patent applications relating to the formulation and intraocular delivery of VEGF antagonists. The first international patent application related to a silicone-free pre-filled plastic syringe has been recently published (International Publication Number WO 2015/173260 Al).
VEGF antagonists ranibizumab and aflibercept are commonly used to treat age dependent eye diseases such as wet macular degeneration. The market size for intraocular anti-VEGF therapy is rapidly increasing with a current volume of about USD 6.9 billion.
Pre-filled syringes have many benefits compared to a vial and a separately provided syringe, such as improved convenience, safety, accuracy, sterility, and affordability. The use of pre-filled syringes results in greater dose precision, in a reduction of the potential for needle stick injuries that can occur while drawing medication from vials, in pre-measured dosage reducing dosing errors and sterility problems due to the need to reconstitute medication or draw it into a syringe, and in less overfilling of the syringe helping to reduce costs by minimising drug waste.
Silicone-free prefilled plastic syringes containing a VEGF antagonist will present an innovative way of drug administration for intraocular injection. Compared to glass syringes this new injection technology offers the potential for improved safety and convenience for patients and healthcare professionals as they are resistant to breakage and have a lower weight. Furthermore, it has been shown that silicone oil from standard glass or plastic syringes might migrate into the drug solution, cause drug inactivation, and accumulates in the vitreous cavity after intravitreal administration of VEGF antagonists.
Dr. Carsten Brockmeyer, CEO of Formycon AG, said "We are pleased to provide a potential improved way to accurately and safely administer VEGF antagonist in the eye. Our patent applications cover a broad range of VEGF antagonist formulations and injection devices. This underlines our mission to develop high quality biosimilars to treat eye diseases, one of the most rapidly growing therapeutic areas."
Formycon and its license partner bioeq GmbH, Holzkirchen, Germany, recently announced the initiation of a pivotal Phase III clinical trial with FYB201, an investigational biosimilar ranibizumab (Lucentis(R)*).
* Lucentis is a registered trademark of Genentech Inc.
About Formycon: Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon's specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.
Contact: Thorsten Schüller Corporate Communications and Investor Relations Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg/Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 Thorsten.schueller@formycon.com // www.formycon.com
Disclaimer: This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. With respect to pipeline products there can be no guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended.
This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.
---------------------------------------------------------------------------
14.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English Company: Formycon AG Fraunhoferstraße 15 82152 Planegg-Martinsried Germany Phone: 089 864667 100 Fax: 089 864667 110 Internet: www.formycon.com ISIN: DE000A1EWVY8 WKN: A1EWVY Listed: Regulated Unofficial Market in Berlin; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------
429447 14.01.2016
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Formycon AGmehr Nachrichten
Analysen zu Formycon AGmehr Analysen
| 10.12.24 | Formycon Outperform | RBC Capital Markets |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.